Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Aref Rahman

Cardiovascular Disease Pittsburgh, PA Medical Doctor

NPI 1669674180 CMS profile 347616

200 Lothrop St, Scaife Hall, 5Th Floor, B571.3, Pittsburgh, PA 15213

Open in the dashboard

General payments

$2,331

84 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$119,139 paid to institutions, not to them · program years 2019–2022

Through program year 2023, Aref Rahman of Pittsburgh, PA is reported in the CMS Open Payments database as having received $2,331 across 84 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $119,139 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 53rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $192 2
2022 General $134 7
2021 General $471 28
2020 General $680 21
2019 General $854 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aref Rahman
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Aref Rahman were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Aref Rahman Cardiovascular Disease median Middle half National median
2019 $854 $450 $127–$1,392 $163
2020 $680 $242 $77–$751 $114
2021 $471 $335 $101–$1,037 $132
2022 $134 $395 $121–$1,211 $149
2023 $192 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Abbott Laboratories $1,177 50 payments
  2. Boston Scientific Corporation $374 5 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $256 7 payments
  4. Shockwave Medical, Inc $229 15 payments
  5. Acist Medical Systems, Inc. $174 1 payment
  6. Cardiovascular Systems Inc. $39 2 payments
  7. Novartis Pharmaceuticals Corporation $34 2 payments
  8. Terumo Medical Corporation $29 1 payment
  9. E.R. Squibb & Sons, L.L.C. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,331 84 payments
Products named General payments · program years 2019–2023
  1. Dragonfly OCT $539 15 payments
  2. LifeVest $256 7 payments
  3. Vascular Lithotripsy $214 14 payments
  4. Xience Sierra Coronary Stent $201 3 payments
  5. GENERAL - STENTS $175 2 payments
  6. CVI Systems $174 1 payment
  7. Synergy $130 1 payment
  8. Optis Coronary Imaging System $125 4 payments
  9. PressureWire FFR $71 10 payments
  10. Xience Sierra Coronary Stent System $60 3 payments
  11. Other $371 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$5,230

Medicare's payments for the services billed

Medicare patients

120

Average age 77

Services billed

149

61 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 62%
Heart failure 52%
Atrial fibrillation 49%
Chronic kidney disease 47%
Diabetes 40%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record